Guanylhydrazone salts, compositions, processes of making, and methods of using
View Patent ↗The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their use.
1. A pharmaceutically acceptable salt, comprising the following compound:
as a salt of at least one pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid has the following formula:
2. A method for making a pharmaceutically acceptable salt, the salt comprising the following compound:
as a salt of at least one pharmaceutically acceptable acid, wherein the acid has the following formula:
the method comprising contacting the compound and at least the acid, to form the salt.
3. A pharmaceutically acceptable composition, comprising the following compound:
as a salt of at least one pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid has the following formula:
and at least one pharmaceutically acceptable carrier.
4. A method for making a pharmaceutically acceptable composition, the composition comprising the following compound:
as a salt of at least one pharmaceutically acceptable acid, wherein the pharmaceutically acceptable acid has the following formula:
and at least one pharmaceutically acceptable carrier;
the method comprising contacting the salt and the pharmaceutically acceptable carrier, to form the composition.
5. The pharmaceutically acceptable salt of claim 1 , wherein the pharmaceutically acceptable salt is a mono salt, having a guanylhydrazone:counterion ratio of 1:1.
6. The pharmaceutically acceptable salt of claim 1 , wherein the pharmaceutically acceptable salt is a di salt, having a guanylhydrazone:counterion ratio of 1:2.
7. The pharmaceutically acceptable salt of claim 1 , wherein the pharmaceutically acceptable acid salt is a tri salt, having a guanylhydrazone:counterion ratio of 1:3.
8. The pharmaceutically acceptable salt of claim 1 , wherein the pharmaceutically acceptable salt is a tetra salt, having a guanylhydrazone counterion ratio of 1:4.
9. The pharmaceutically acceptable composition of claim 3 , wherein the pharmaceutically acceptable salt is a mono salt, having a guanylhydrazone:counterion ratio of 1:1.
10. The pharmaceutically acceptable composition of claim 3 , wherein the pharmaceutically acceptable salt is a di salt, having a guanylhydrazone:counterion ratio of 1:2.
11. The pharmaceutically acceptable composition of claim 3 , wherein the pharmaceutically acceptable salt is a tri salt, having a guanylhydrazone:counterion ratio of 1:3.
12. The pharmaceutically acceptable composition of claim 3 , wherein the pharmaceutically acceptable salt is a tetra salt, having a guanylhydrazone:counterion ratio of 1:4.